Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AERAS-485
MVA85A · 1 trial · 1 indication
To evaluate the safety profile of multiple doses of AERAS-402 alone, compared to one and two doses of AERAS-402 followed by MVA85A in healthy, BCG vaccinated adults, measured by number and severity of local and systemic adverse events
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Two doses of AERAS-402 (1x10\^11 vp intramuscular injection) followed by one dose of MVA85A (1x10\^8 pfu intradermal injection) |
| Group B | EXPERIMENTAL | One dose of AERAS-402 (1x10\^11 vp intramuscular injection) followed by one dose of MVA85A (1x10\^8 pfu intradermal injection) |
| Group C | EXPERIMENTAL | Three doses of AERAS-402 (1x10\^11 vp intramuscular injection) |
| Name | Type | Description |
|---|---|---|
| AERAS-402 | BIOLOGICAL | Intramuscular needle injection 1x10\^11 vp |
| MVA85A | BIOLOGICAL | Intradermal needle injection 1x10\^8 pfu |
Inclusion Criteria: Subjects must meet all of the following criteria to enter the trial: * Healthy adult aged 18-55 years * Resident in or near Oxford (for CCVTM) or Birmingham (for WTCRF; and able to travel to Oxford for vaccinations) for the duration of the trial period * No relevant findings in...
Top 2 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT164a1, BNT164b1 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | Ganfeborole |
MVA85A is an investigational product being developed for tuberculosis, an infectious disease. It has been studied in a Phase 1 clinical trial conducted in the United Kingdom that enrolled 40 healthy adult volunteers aged 18 years and older. It is not an approved product and remains in clinical development.
MVA85A is being studied for tuberculosis, in a Phase 1 trial that evaluated it alongside the tuberculosis vaccine AERAS-402. The completed study enrolled 40 healthy volunteers in the United Kingdom and assessed safety in adults 18 years and older. MVA85A is investigational and has no approved use.
MVA85A is being developed by Emergent BioSolutions Inc., which trades under the ticker EBS. The company is the developer associated with the Phase 1 program for this tuberculosis candidate.
MVA85A is in Phase 1 clinical development for tuberculosis. One Phase 1 trial has been completed, and no trials are currently active. The program enrolled 40 participants in total. MVA85A is investigational and is not an approved product.
MVA85A has been studied in the Phase 1 trial NCT01683773, titled Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A. That trial was completed, enrolled 40 healthy volunteers, and was conducted in the United Kingdom. It was a controlled study without randomization or double blinding.
Across its clinical program, MVA85A has enrolled 40 participants in total, all in the completed Phase 1 trial NCT01683773. That study was conducted in the United Kingdom and included healthy volunteers aged 18 years and older.